|From: blacksheep (Rep: 332)||Date: 04/12/2017 08:32|
|Forum: Neurocrine Biosciences - Msg #1114||Thread #673920731 (Rec: 0) |
|$100/sh stock? BMO saying the positive Ingrezza label along with other catalysts opens pathway |
Neurocrine Biosciences (NASDAQ:NBIX) +14.3% AH after saying it received FDA approval of its Ingrezza capsules as the first and only approved treatment for adults with tardive dyskinesia neurological disorder.
NBIX says the drug will be in the distribution channel next week and will be available through a select pharmacy network.
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.